urokinas
uk
produc
mild
prolong
thrombolyt
state
minim
disturb
blood
coagul
effect
highli
control
administ
bodi
weight
adjust
dosag
addit
uk
much
cheaper
tissu
plasminogen
activ
rtpa
reliabl
efficaci
safeti
well
low
cost
made
uk
valuabl
agent
pulmonari
embol
pe
thrombolyt
therapi
wide
use
develop
countri
current
singl
uk
regimen
shown
superior
anoth
treat
pe
load
dose
iukg
follow
iukghour
hour
h
recommend
acut
pe
treatment
american
colleg
chest
physician
accp
guidelin
howev
earlier
studi
show
bleed
incid
regimen
high
reduc
infus
time
demonstr
promis
result
decreas
major
bleed
rate
addit
observ
h
ukg
h
regim
superior
thrombolyt
effect
h
regimen
fresh
thrombi
canin
pe
model
potenti
advantag
lower
bleed
risk
increas
effect
fresh
thrombi
conveni
lower
cost
h
becom
promis
regimen
howev
direct
comparison
regimen
accp
recommend
h
regimen
studi
compar
h
h
regimen
treat
acut
pe
random
control
multicent
trial
acut
pe
patient
either
haemodynam
instabilitycardiogen
shock
anatom
massiv
obstruct
right
ventricular
dysfunct
rvd
enrol
studi
efficaci
assess
improv
right
ventricular
rv
function
pulmonari
perfus
vq
scan
pulmonari
arteri
obstruct
ct
pulmonari
angiogram
ctpa
h
treatment
safeti
evalu
incid
bleed
pe
recurr
death
rate
prospect
random
open
label
multicent
trial
conduct
juli
februari
china
trial
suspend
nearli
one
year
due
sever
acut
respiratori
syndrom
sar
outbreak
central
steer
committe
form
charg
studi
design
protocol
develop
standard
qualiti
control
data
verif
analysi
studi
protocol
review
approv
institut
board
ethic
committe
particip
center
patient
enrol
studi
central
randomli
assign
treatment
group
standard
computer
random
program
clinic
inform
imag
patient
review
independ
member
steer
committe
patient
age
year
acut
pe
symptom
occur
within
day
time
enrol
screen
diagnos
confirm
either
high
probabl
vq
scan
presenc
intralumin
fill
defect
spiral
ctpa
indic
thrombolyt
therapi
patient
haemodynam
instabl
cardiogen
shock
patient
massiv
pulmonari
arteri
obstruct
obstruct
lobe
ctpa
perfus
defect
segment
vq
scan
combin
right
ventricular
dysfunct
rvd
pulmonari
hypertens
echocardiograph
examin
studi
shown
patient
high
risk
fatal
condit
may
benefit
thrombolyt
therapi
patient
exclud
receiv
parenter
heparin
hour
thrombolyt
contraind
written
inform
consent
obtain
patient
elig
subject
randomli
assign
either
h
group
bolu
ukg
follow
intraven
hour
h
group
ukg
intraven
infus
hour
figur
random
perform
central
control
manner
accord
standard
random
program
uk
use
studi
guangzhou
techpool
bio
pharma
co
ltd
china
uk
infus
activ
partial
thromboplastin
time
aptt
test
valu
less
sec
subcutan
inject
low
molecular
weight
heparin
nadroparin
antifactor
xa
iukg
given
everi
hour
overlap
oral
anticoagul
therapi
warfarin
start
day
nadroparin
inject
maintain
intern
normal
ratio
inr
nadroparin
stop
day
warfarin
ad
inr
stabil
least
day
warfarin
continu
use
least
month
subsequ
dose
adjust
maintain
inr
within
rang
target
valu
echocardiogram
perform
analyz
two
echocardiograph
right
ventricular
function
analyz
improv
right
left
ventricular
enddiastol
diamet
ratio
parastern
longaxi
view
rvedlv
rightleft
ventricular
dimens
ratio
rvlv
dimens
estim
systol
pulmonari
arteri
pressur
spap
absenc
left
ventricular
diseas
mitral
valv
diseas
previous
report
spap
measur
use
follow
equat
spap
vtr
right
atrial
pressur
rap
rap
estim
accord
respiratori
motion
ivc
lung
scan
independ
review
evalu
two
specialist
use
method
describ
previous
anatom
segment
lung
review
defect
within
segment
score
accord
level
perfus
reduct
locat
sever
thrombu
obstruct
pulmonari
vascular
bed
review
evalu
helic
ctpa
score
system
describ
previou
studi
index
defin
product
n
n
valu
proxim
clot
site
equal
number
segment
branch
aris
distal
degre
obstruct
partial
obstruct
score
total
obstruct
grade
advers
event
monitor
day
initi
treatment
uk
death
classifi
due
pe
bleed
caus
includ
myocardi
infarct
unknown
caus
major
bleed
includ
fatal
bleed
intracrani
hemorrhag
ich
drop
hemoglobin
concentr
least
gl
requir
transfus
ml
red
blood
cell
within
h
initi
uk
therapi
minor
bleed
includ
bleed
hemoglobin
concentr
drop
less
gl
recurr
pe
confirm
vq
scan
andor
spiral
ctpa
blood
urea
nitrogen
bun
creatinin
cr
monitor
whole
interv
studi
method
kidney
protect
includ
encourag
patient
drink
abundantli
recommend
ward
ensur
adequ
hydrat
patient
hour
calcul
sampl
size
demonstr
patient
requir
show
differ
point
treatment
group
percent
reduct
score
ctpa
h
onset
thrombolysi
power
twosid
level
signific
assum
standard
deviat
point
data
analyz
accord
intentiontotreat
principl
categori
data
compar
use
chisquar
test
fisher
test
tabl
comparison
continu
data
treatment
group
perform
use
test
willcoxon
test
appropri
chang
measur
echocardiogram
vq
scan
ctpa
time
analyz
use
repeat
measur
analysi
varianc
subgroup
analysi
also
conduct
base
homodynam
statu
massiv
pe
report
p
valu
p
statist
signific
post
hoc
subgroup
analysi
also
conduct
base
homodynam
statu
massiv
pe
use
unpair
test
chisquar
test
fisher
test
appropri
patient
acut
pe
preselect
particip
center
patient
confirm
ctpa
patient
evalu
vq
time
inelig
predefin
exclus
criteria
among
enrol
studi
assign
h
assign
h
figur
signific
differ
two
group
baselin
characterist
tabl
improv
pulmonari
arteri
pressur
rv
function
evalu
echocardiogram
baselin
h
followup
evalu
rvedlv
ratio
rvlv
dimens
ratio
spap
perform
patient
h
group
h
group
treatment
group
show
significantli
progress
improv
right
ventricular
function
determin
three
measur
signific
differ
found
two
treatment
group
measur
differ
time
point
figur
improv
lung
perfus
determin
vq
lung
scan
baselin
h
followup
vq
lung
scan
conduct
patient
h
h
group
treatment
achiev
signific
improv
pulmonari
vascular
perfus
defect
similar
score
h
post
rtpa
administr
figur
improv
pulmonari
arteri
obstruct
assess
ctpa
patient
underw
baselin
h
follow
ctpa
uk
h
group
uk
h
group
quantit
assess
show
two
treatment
group
substanti
reduct
pe
obstruct
index
differ
time
point
treatment
signific
differ
group
figur
distribut
signific
improv
slight
improv
chang
wors
similar
two
regimen
tabl
mortal
rate
low
group
one
patient
h
group
die
recurr
pe
two
patient
h
group
die
one
die
minut
initi
uk
due
pe
combin
respiratori
congest
heart
failur
one
die
day
initi
treatment
due
acut
myocardi
infarct
incid
overal
bleed
two
group
similar
h
group
vs
h
group
incid
major
bleed
minor
bleed
also
similar
two
group
intracrani
bleed
episod
found
either
group
fatal
bleed
episod
report
either
group
import
emphas
major
major
bleed
occur
day
uk
infus
one
patient
major
bleed
episod
uk
h
group
one
patient
uk
h
group
directli
associ
uk
occur
hour
initi
uk
one
fatal
recurr
pe
report
day
posttreat
h
group
episod
recurr
symptomat
pe
report
either
group
tabl
subgroup
comparison
conduct
separ
patient
hemodynam
instabl
patient
massiv
pulmonari
arteri
obstruct
patient
hemodynam
instabl
h
h
produc
similar
progress
improv
pulmonari
arteri
obstruct
tabl
addit
differ
found
two
treatment
term
death
bleed
pe
recurr
patient
similarli
two
treatment
show
similar
efficaci
safeti
patient
massiv
pulmonari
vascular
obstruct
combin
rvd
previou
studi
demonstr
h
uk
h
induc
rapid
thrombolysi
pulmonari
circul
acut
massiv
pe
increas
evid
suggest
uk
infus
dosag
durat
reduc
shown
million
iu
uk
infus
h
follow
heparin
therapi
effect
safe
rtpa
mg
h
regimen
much
lower
dose
iukg
uk
h
shown
effect
without
sever
bleed
allerg
reaction
studi
demonstr
h
regimen
much
lower
dose
iukg
use
previou
trial
million
h
produc
similar
improv
pulmonari
circul
right
heart
dysfunct
h
regimen
practic
use
thrombolyt
therapi
instead
anticoagul
therapi
alon
treat
patient
extens
pulmonari
arteri
obstruct
defin
obstruct
exceed
pulmonari
vasculatur
occlus
two
lobar
arteri
combin
echocardiograph
sign
rv
overload
even
present
normal
system
arteri
pressur
patient
risk
deterior
condit
wors
prognosi
studi
shown
patient
may
benefit
thrombolyt
therapi
current
guidelin
also
suggest
thrombolyt
therapi
may
consid
select
patient
intermedi
risk
pe
thorough
consider
condit
increas
risk
bleed
studi
therefor
includ
patient
subgroup
analysi
present
paper
predefin
protocol
result
enough
power
draw
conclus
data
although
inclus
may
potenti
make
efficaci
comparison
two
regimen
less
conclus
subgroup
analysi
show
h
regimen
effect
patient
intermedi
risk
pe
also
patient
hemodynam
instabl
nevertheless
futur
studi
anticoagul
control
patient
intermedi
risk
pe
valuabl
determin
whether
thrombolyt
therapi
inde
benefici
patient
current
give
lmwh
routin
practic
high
risk
pe
patient
howev
subcutan
inject
lmwh
shown
produc
greater
efficaci
less
hemorrhag
risk
improv
conveni
clinic
research
practic
consid
advantag
would
safe
use
lmwh
high
risk
pe
patient
thrombolyt
therapi
mortal
rate
studi
compar
report
previou
clinic
trial
although
patient
h
group
die
two
patient
die
earli
stage
due
sever
diseas
self
commod
patient
death
h
group
due
recurr
pe
major
bleed
rate
studi
compar
previous
report
trial
overal
bleed
rate
patient
lower
ukep
studi
high
incid
hemorrhag
complic
observ
earli
studi
mainli
attribut
invas
procedur
angiograph
hemodynam
measur
allerg
reaction
observ
studi
one
major
criteria
evalu
thrombolyt
therapi
recurr
embol
occur
first
week
followup
result
high
mortal
rate
recurr
studi
similarli
low
group
one
patient
h
group
die
recurr
pe
day
initi
treatment
recurr
pe
report
h
group
earli
thrombolyt
therapi
may
reduc
incid
recurr
embol
studi
prolong
observ
desir
compar
recurr
two
differ
regimen
limit
studi
firstli
smaller
sampl
size
common
limit
pe
thrombolyt
studi
prevent
us
achiev
power
efficaci
safeti
analysi
particularli
true
smaller
sampl
size
subgroup
comparison
efficaci
advers
event
two
treatment
hemodynam
anatom
massiv
pe
subgroup
therefor
could
draw
confirm
conclus
studi
larger
sampl
size
desir
determin
efficaci
safeti
uk
h
regimen
seriou
imbal
number
patient
two
treatment
group
attribut
smaller
case
number
assign
vs
uk
infus
larger
sampl
size
central
random
avoid
type
imbal
extent
secondli
patient
extens
pulmonari
arteri
obstruct
rv
dysfunct
control
group
heparin
alon
includ
futur
studi
anticoagul
control
valuabl
determin
whether
thrombolyt
therapi
inde
benefici
patient
peitho
pulmonari
embol
thrombolysi
studi
go
determin
whether
thrombolysi
improv
outcom
patient
present
highrisk
submass
acut
pe
compar
anticoagul
alon
demonstr
clinic
benefit
tenecteplas
placebo
normotens
patient
acut
pe
right
ventricular
dysfunct
random
trial
assess
potenti
longterm
benefit
thrombolyt
therapi
acut
massiv
pe
except
studi
report
meneveau
et
al
studi
suggest
regimen
streptokinas
routin
use
patient
massiv
pe
maintain
cardiac
output
without
obvious
compromis
efficaci
safeti
longterm
followup
studi
would
provid
valuabl
inform
thrombolyt
therapi
conclus
studi
demonstr
h
iukg
regimen
display
similar
efficaci
safeti
h
regimen
treat
acut
pe
either
hemodynam
instabl
massiv
pulmonari
arteri
obstruct
given
conveni
lower
cost
similar
efficaci
safeti
h
regim
suggest
bodi
weight
adjust
h
regimen
could
use
pe
treatment
studi
requir
evalu
short
longterm
outcom
differ
uk
thrombolyt
regimen
accp
american
colleg
chest
physician
ctpa
comput
tomograph
pulmonari
angiographi
dvt
deep
vein
thrombosi
ich
intracrani
hemorrhag
inr
intern
normal
ratio
lmwh
low
molecular
weight
heparin
pe
pulmonari
embol
rvd
right
ventricular
dysfunct
rvedlv
right
left
ventricular
enddiastol
diamet
ratio
parastern
longaxi
view
spap
systol
pulmonari
arteri
pressur
uk
urokinas
vq
ventil
perfus
lung
scan
author
declar
compet
interest
author
made
substanti
contribut
concept
design
acquisit
data
analysi
interpret
data
review
approv
final
manuscript
contribut
significantli
studi
dr
cw
zgz
yhi
contribut
equal
work
cw
princip
investig
take
full
respons
integr
submiss
public
involv
studi
design
part
steer
committe
zgz
full
access
data
studi
take
respons
integr
data
accuraci
data
analysi
respons
data
verif
analysi
draft
manuscript
yhi
full
access
data
studi
take
respons
integr
data
accuraci
data
analysi
ydi
respons
patient
enrol
data
collect
zzc
respons
patient
enrol
data
collect
lrl
full
access
data
studi
take
respons
integr
data
accuraci
data
analysi
hpd
respons
patient
enrol
data
collect
kwh
respons
patient
enrol
data
collect
wxl
involv
studi
design
part
steer
committe
zhz
involv
studi
design
part
steer
committe
xsc
involv
studi
design
part
steer
committe
yh
respons
data
verif
analysi
draft
manuscript
contribut
whole
team
china
venou
thromboembol
studi
group
crucial
success
studi
contribut
author
also
grate
dr
charl
hale
lan
zhao
valuabl
suggest
manuscript
